Literature DB >> 443884

Acetylator phenotype in spontaneous SLE and rheumatoid arthritis.

D H Lawson, D A Henry, J Lowe, P Reavey, J A Rennie, A Solomon.   

Abstract

Acetylator phenotype was determined in 22 patients with spontaneous systemic lupus erythematosus and the proportion of 'slow' acetylators compared with that obtained in a group of patients with rheumatoid arthritis and a group of healthy controls. 73% of the SLE group were designated 'slow' compared with 72% of the rheumatoid group and 64% of the control group. These differences were not significant.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 443884      PMCID: PMC1000345          DOI: 10.1136/ard.38.2.171

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  HUMAN ACETYLATION POLYMORPHISM.

Authors:  D A EVANS; T A WHITE
Journal:  J Lab Clin Med       Date:  1964-03

2.  Genetic control of isoniazid metabolism in man.

Authors:  D A EVANS; K A MANLEY; V A McKUSICK
Journal:  Br Med J       Date:  1960-08-13

Review 3.  Disease and acetylation polymorphism.

Authors:  P K Lunde; K Frislid; V Hansteen
Journal:  Clin Pharmacokinet       Date:  1977 May-Jun       Impact factor: 6.447

4.  Simplified method for determining acetylator phenotype.

Authors:  H Schröder
Journal:  Br Med J       Date:  1972-08-26

5.  Relation of hydralazine plasma concentration to dosage and hypotensive action.

Authors:  R Zacest; J Koch-Weser
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

6.  The polymorphic acetylation of dapsone in man.

Authors:  R Gelber; J H Peters; G R Gordon; A J Glazko; L Levy
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

7.  Evaluation of the sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal diseases.

Authors:  L Molin; R Larsson; E Karlsson
Journal:  Acta Med Scand       Date:  1977

8.  The acetylator phenotype of patients with systemic lupus erythematosus.

Authors:  M M Reidenberg; J H Martin
Journal:  Drug Metab Dispos       Date:  1974 Jan-Feb       Impact factor: 3.922

Review 9.  Drug-induced antinuclear antibodies and lupus syndromes.

Authors:  D Alarcón-Segovia
Journal:  Drugs       Date:  1976       Impact factor: 9.546

10.  Spontaneous systemic lupus erythematosus and acelylator phenotype.

Authors:  R Larsson; E Karlsson; L Molin
Journal:  Acta Med Scand       Date:  1977
  10 in total
  9 in total

1.  N-acetyltransferase-2 genotypes among patients with rheumatoid arthritis attending Jordan University Hospital.

Authors:  Muna K Oqal; Khader N Mustafa; Yacoub M Irshaid
Journal:  Genet Test Mol Biomarkers       Date:  2012-06-25

Review 2.  Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review.

Authors:  T Pullar; H A Capell
Journal:  Drugs       Date:  1986       Impact factor: 9.546

3.  Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis.

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Ann Rheum Dis       Date:  1985-12       Impact factor: 19.103

Review 4.  Survey of the human acetylator polymorphism in spontaneous disorders.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1984-08       Impact factor: 6.318

Review 5.  Acetylator phenotype and lupus erythematosus.

Authors:  J P Uetrecht; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

Review 6.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

7.  Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.

Authors:  Y Horai; T Ishizaki; T Sasaki; G Koya; K Matsuyama; S Iguchi
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

8.  Drug acetylation and expression of lupus erythematosus.

Authors:  J R Marsden; G G Mason; P R Coburn; M D Rawlins; S Shuster
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Acetylator polymorphism in discoid lupus erythematosus.

Authors:  J M Ladero; L C Jiménez; M J Fernández; A Robledo
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.